Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. D. Chalmers, D. Kilpatrick, B. McHugh, P. Mandal, M. Smith, C. Doherty, J. Govan, A. T. Hill (Edinburgh, United Kingdom). Mannose binding lectin deficiency is associated with disease severity in patients with non-cystic fibrosis bronchiectasis. Eur Respir J 2011; 38: Suppl. 55, 2538

Member's Comments

No comment yet.

Related content which might interest you: Stable non-cystic fibrosis bronchiectasis is associated with deficiency of the pattern recognition molecule L-Ficolin Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 Multiple faces of non-cystic fibrosis bronchiectasis: defining etiology and disease severity Source: International Congress 2017 – Management of asthma in different situations Year: 2017 Clinical and functional profile of patients with non-cystic fibrosis bronchiectasis according to the presence of chronic bronchial infection Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis Year: 2019 IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 373s Year: 2007 DLCO predicts disease severity and mortality in patients with non-cystic fibrosis bronchiectasis Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 HRCT features in patients with severe asthma and non-cystic fibrosis bronchiectasis. Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020 Aetiology of non cystic fibrosis bronchiectasis and its correlation with the site of pulmonary damage Source: Eur Respir J 2003; 22: Suppl. 45, 504s Year: 2003 Prevalence of non-cystic fibrosis bronchiectasis in patients with severe asthma: a real-life study Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020 Factors affecting progression of lung disease among patients with cystic fibrosis Source: International Congress 2019 – Physiology of cystic fibrosis Year: 2019 Tumor-associated antigens in acute exacerbation of idiopathic pulmonary fibrosis: Associations with disease activity Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Factors associated with recurrence of severe exacerbations in Non-cystic fibrosis bronchiectasis in developping countries. Source: International Congress 2019 – Clinical problems Year: 2019 Arginase in patients with cystic fibrosis airway disease Source: Annual Congress 2004 - Cystic fibrosis in the 21st century: cutting edge investigations, taxing problems Year: 2004 Frequency and pathogenicity of rhinovirus associated pulmonary exacerbations in patients with cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Screening for cystic fibrosis among high risk group patients with chronic lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 340s Year: 2002 Autoantibodies in patients with idiopathic pulmonary fibrosis Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 Early determinants of lung disease in children with cystic fibrosis Source: Virtual Congress 2020 – New frontiers in cystic fibrosis imaging and lung physiology Year: 2020 Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis Source: ERJ Open Res, 4 (1) 00111-2017; 10.1183/23120541.00111-2017 Year: 2018 The lung microbiome in chronic suppurative lung disease: cystic fibrosis and non-cystic fibrosis bronchiectasis Source: Eur Respir Monogr 2019; 83: 158-172 Year: 2019 Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019 Year: 2020 Endotrophin is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020